An inhibitor of JAK1 exhibits "remarkable" activity in T-cell lymphoma.

Published Date: 18 Dec 2023

An accelerated approval application for golidocitinib will be based on phase II results.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The risk of cancer is decreased by following international health recommendations.

2.

Adipocytes in the bone marrow offer early indicators of the development of multiple myeloma from MGUS.

3.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

4.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

5.

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot